Effects of statin, aspirin or metformin use on recurrence free and overall survival in patients with biliary tract cancer

Mairead Mcnamara, P Aneja, LW Le, AM Horgan, E McKeever, JJ Knox

    Research output: Contribution to conferencePoster

    Abstract

    Background: BTCs include intrahepatic (IHC), hilar, distal bile duct (DBD), and gallbladder carcinoma (GBC). Statins, aspirin and metformin may have antineoplastic properties. The impact of their use on overall survival and the recurrence free survival of patients who had curative resection of BTC has not been evaluated. Methods: Baseline demographics and use of statins, aspirin or metformin at diagnosis were evaluated in 913 patients with BTC from 01/87 - 07/13 treated at Princess Margaret Cancer Center, Toronto. Their prognostic significance for recurrence free and overall survival was determined using a Cox proportional hazards model. Results: The median age at diagnosis for the entire cohort was 65.7 years (range 23.7-93.7). 795 patients had a performance status <2 and 461 (50.5%) were male. The primary site was GBC in 310 (34%) patients, DBD in 212 (23%), IHC in 200 (22%) and hilar in 191 (21%). Curative surgical resection was performed in 355 (39%) patients. Among the entire cohort of 913 patients, 151 (16.5%) reported statin use at diagnosis. Atorvastatin was the statin used in 55% of patients. 146 (16%) reported aspirin use and 81 (9%) reported metformin use at diagnosis. Age (p=0.05, p
    Original languageEnglish
    Publication statusPublished - 2014
    Event2014 Gastrointestinal Cancers Symposium - San Francisco
    Duration: 1 Jan 1824 → …

    Conference

    Conference2014 Gastrointestinal Cancers Symposium
    CitySan Francisco
    Period1/01/24 → …

    Fingerprint

    Dive into the research topics of 'Effects of statin, aspirin or metformin use on recurrence free and overall survival in patients with biliary tract cancer'. Together they form a unique fingerprint.

    Cite this